CA2478145A1 - Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer - Google Patents
Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer Download PDFInfo
- Publication number
- CA2478145A1 CA2478145A1 CA002478145A CA2478145A CA2478145A1 CA 2478145 A1 CA2478145 A1 CA 2478145A1 CA 002478145 A CA002478145 A CA 002478145A CA 2478145 A CA2478145 A CA 2478145A CA 2478145 A1 CA2478145 A1 CA 2478145A1
- Authority
- CA
- Canada
- Prior art keywords
- nitric oxide
- cancer
- cells
- tumor
- mimetic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
L'invention concerne des procédés et des formulations permettant d'inhiber, de traiter et de prévenir un phénotype cellulaire malin, une cellule, une tumeur et/ou une maladie. L'administration de substances mimétiques d'oxyde nitrique, en faibles doses, suffit pour accroître, restaurer ou maintenir la signalisation induite par l'oxyde nitrique dans des cellules, de manière que ces phénotypes cellulaires malins, ces cellules, ces tumeurs et/ou ces maladies soient inhibés ou prévenus. Ces procédés et formulations sont particulièrement utiles pour le traitement et la prévention du cancer chez des animaux.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36296902P | 2002-03-06 | 2002-03-06 | |
US60/362,969 | 2002-03-06 | ||
US36262002P | 2002-03-07 | 2002-03-07 | |
US60/362,620 | 2002-03-07 | ||
PCT/CA2003/000313 WO2003074082A1 (fr) | 2002-03-06 | 2003-03-06 | Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2478145A1 true CA2478145A1 (fr) | 2003-09-12 |
Family
ID=27791719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002478145A Abandoned CA2478145A1 (fr) | 2002-03-06 | 2003-03-06 | Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1492567A1 (fr) |
JP (1) | JP2005527510A (fr) |
AU (1) | AU2003208228A1 (fr) |
CA (1) | CA2478145A1 (fr) |
WO (1) | WO2003074082A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
PL2348114T3 (pl) | 2004-04-21 | 2019-08-30 | Alexion Pharmaceuticals, Inc. | Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość |
US7329495B2 (en) | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
CN101001623B (zh) * | 2004-06-10 | 2010-11-17 | 日本化药株式会社 | 抗癌效果增强剂 |
CA2619779C (fr) | 2004-08-19 | 2013-03-12 | Switch Biotech Ag | Utilisation d'un inhibiteur de la pde5 pour le traitement et la prevention de troubles caracterises par une hypopigmentation |
ATE438403T1 (de) * | 2004-08-19 | 2009-08-15 | Switch Biotech Llc | Verwendung eines pde5-hemmers zur behandlung und vorbeugung von hypopigmentierungsstörungen |
AU2012203798B2 (en) * | 2005-08-12 | 2013-11-07 | Northrop Grumman Systems Corporation | O-nitro compounds, pharmaceutical compositons thereof and uses thereof |
US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
EP2237788A4 (fr) * | 2007-12-27 | 2013-06-05 | Aires Pharmaceuticals Inc | Composés permettant d'obtenir du nitrite et de l'oxyde nitrique aérosolisés et leurs utilisations |
JP5467259B2 (ja) * | 2008-03-13 | 2014-04-09 | 国立大学法人 千葉大学 | シスプラチン効果増強剤及び抗癌剤キット |
AU2009244790B2 (en) * | 2008-05-09 | 2013-09-12 | Duke University | Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells |
AU2011350066A1 (en) | 2010-12-27 | 2013-07-11 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
WO2012118042A1 (fr) * | 2011-02-28 | 2012-09-07 | 独立行政法人国立循環器病研究センター | Agent médicinal pour l'inhibition de la métastase d'une tumeur maline |
JP5842367B2 (ja) * | 2011-04-07 | 2016-01-13 | ニプロ株式会社 | 抗癌剤増感剤 |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
WO2015157471A1 (fr) | 2014-04-08 | 2015-10-15 | The Methodist Hospital | Compositions inhibitrices d'inos et leur utilisation comme agents thérapeutiques de cancer du sein |
WO2016007873A1 (fr) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions et méthodes de traitement de la craniosynostose |
CN107405390A (zh) | 2014-12-05 | 2017-11-28 | 阿雷克森制药公司 | 用重组碱性磷酸酶治疗癫痫 |
CA2973883A1 (fr) | 2015-01-28 | 2016-08-04 | Alexion Pharmaceuticals, Inc. | Methodes de traitement d'un sujet atteint d'une deficience en phosphatase alcaline |
WO2017031114A1 (fr) | 2015-08-17 | 2017-02-23 | Alexion Pharmaceuticals, Inc. | Fabrication de phosphatases alcalines |
EP3355904A4 (fr) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | Identification de régimes posologiques efficaces pour une thérapie de l'hypophosphatasie de remplacement de l'enzyme phosphatase alcaline non spécifique à des tissus (tnsalp) |
WO2017074466A1 (fr) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de la craniosynostose chez un patient |
US11065306B2 (en) | 2016-03-08 | 2021-07-20 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
EP3436052A4 (fr) | 2016-04-01 | 2019-10-09 | Alexion Pharmaceuticals, Inc. | Traitement d'une faiblesse musculaire à l'aide de phosphatases alcalines |
WO2017173395A1 (fr) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Méthodes de traitement de l'hypophosphatasie chez les adolescents et les adultes |
EP3464573A4 (fr) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | Impact du métal sur la production des phosphatases alcalines |
WO2018035420A1 (fr) | 2016-08-18 | 2018-02-22 | Alexion Pharmaceuticals, Inc. | Procédés de traitement de la trachéobronchomalacie |
BR112019020506A2 (pt) | 2017-03-31 | 2020-08-04 | Alexion Pharmaceuticals, Inc. | métodos para o tratamento de hipofosfatasia (hpp) em adultos e adolescentes |
EP3773684A1 (fr) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Production de glycoprotéines |
BR112023016048A2 (pt) | 2021-02-12 | 2023-11-14 | Alexion Pharma Inc | Polipeptídeos de fosfatase alcalina e métodos de uso dos mesmos |
CN114869894A (zh) * | 2022-05-10 | 2022-08-09 | 福州大学 | 一种小分子化合物在制备作为尿激酶受体抑制剂药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LV11542B (en) * | 1995-03-30 | 1997-02-20 | Latvijas Organiskas Sintezes Instituts | Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof |
AU8398398A (en) * | 1997-07-14 | 1999-02-10 | Brigham And Women's Hospital | Modification of nitric oxide activity to treat fas-induced pathologies |
EP1251840A2 (fr) * | 2000-01-26 | 2002-10-30 | Cedars-Sinai Medical Center | Procede utilisant l'activation des canaux potassiques pour l'apport d'un medicament jusqu'a une region anormale du cerveau et/ou jusqu'a une tumeur maligne |
US20010038832A1 (en) * | 2000-04-11 | 2001-11-08 | Benjamin Bonavida | Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity |
JP2003531179A (ja) * | 2000-04-26 | 2003-10-21 | クイーンズ ユニバーシティ アット キングストン | 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法 |
-
2003
- 2003-03-06 JP JP2003572598A patent/JP2005527510A/ja active Pending
- 2003-03-06 WO PCT/CA2003/000313 patent/WO2003074082A1/fr active Application Filing
- 2003-03-06 CA CA002478145A patent/CA2478145A1/fr not_active Abandoned
- 2003-03-06 AU AU2003208228A patent/AU2003208228A1/en not_active Abandoned
- 2003-03-06 EP EP03706181A patent/EP1492567A1/fr not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
WO2003074082A1 (fr) | 2003-09-12 |
AU2003208228A1 (en) | 2003-09-16 |
EP1492567A1 (fr) | 2005-01-05 |
JP2005527510A (ja) | 2005-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8168232B2 (en) | Formulations and methods of using nitric oxide mimetics in cancer treatment | |
CA2478145A1 (fr) | Formulations et procedes d'utilisation de substances mimetiques de l'oxyde nitrique dans le traitement du cancer | |
US6946484B2 (en) | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype | |
US20050142217A1 (en) | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype | |
AU2001250221A1 (en) | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype | |
US6689787B1 (en) | Method of using an integrin antagonist and radiation therapy as combination therapy in the treatment of neoplasia | |
WO2015198266A1 (fr) | Administration intermittente d'inhibiteur de mdm2 | |
US11129830B2 (en) | PAC-1 combination therapy | |
EP1502604A1 (fr) | Utilisation de substances mimetiques de l'oxide nitrique dans le traitement du cancer | |
KR100858946B1 (ko) | 초기 유방암을 가진 폐경후 여성의 치료를 위한아나스트로졸의 용도 | |
US20220323474A1 (en) | Drug combination treatments using bone-targeting therapeutics for bone and bone-related disease | |
US20220409582A1 (en) | Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma | |
AU2013208649B2 (en) | Combination therapy for the treatment of cancer | |
WO2021048419A1 (fr) | Polythérapies comprenant du tramétinib pour le traitement du cholangiocarcinome | |
EP2432480B1 (fr) | Compositions et procédés pour traiter une arthrite inflammatoire | |
RU2776995C2 (ru) | Виды комбинированной лекарственной терапии с использованием лекарственных препаратов, целенаправленно воздействующих на костную ткань, для лечения костей и заболевания, связанного с костной тканью | |
TW202128213A (zh) | 一種用於緩解癌症化療引起抗藥性並對化療增效之醫藥組合物及其用途 | |
JP2002524481A (ja) | 他の抗癌剤または理学療法と組み合わせたスクアラミンを使用する癌腫の処置 | |
WO2011056663A1 (fr) | Procédé de traitement du cancer en utilisant une combinaison d'un agent alkylant bifonctionnel et d'inhibiteurs de la réparation de l'adn | |
JP2010507628A (ja) | 骨ガンの処置又は予防のためのmtki1の使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |